Dr. Santo Domingo –The Ministry of Public Health’s high-priced drug program has come under heavy criticism from politicians, the media and the public in recent months over delivery delays, bureaucracy and hurdles in procurement and hiring laws.
Chronic diseases such as growth disorders, cancer, rheumatoid arthritis, systemic lupus erythematosus, kidney disease are some of the more than one hundred conditions covered by the plan.
Public Procurement and Contracts Director Carlos Pimentel has drawn attention in recent days with statements to the media in which he said the social policy was “unsustainable for the government”. It was later clarified that this was a call to the Health Risk Regulatory Agency (ARS) to cover more high-cost drugs.
According to a recent press release from the Ministry of Public Health, 1,300 new patients have been admitted this year and timely treatment has been provided to more than 16,000 beneficiaries.
For its part, the Essential Medicines Program (PROMESE/CAL) manages a P7.3 billion budget for the purchase of these medicines.
As part of the program, they recently executed two procurement processes for high-cost Medicines Access Authority (DAMAC)-needed drugs to meet demand from May to November of this year.
During these two procurements, 75 molecules were procured for which a budget of 3,406,760,728 million pesos was allocated.
Within pathology, the greatest need is in different types of cancer, which account for 41% of the chronic conditions covered by the program.
Major diseases include: Tongue, prostate, colon, lung, rectum, papillary, head and neck, tonsils, cervix, pharynx, breast, ovary, pancreas, kidney; and thyroid. Idiopathic arthritis, psoriasis, rheumatoid arthritis. Endometriosis, Behcet’s disease, hepatitis C, hidradenitis suppurativa, arterial hypertension, pulmonary hypertension, and renal failure.
Abiraterone Acetate, Abiraterone Acetate, Goserelin Acetate, Goserelin Acetate, Extended Release Implants, Leuprolide Acetate. Zoledronic acid, zoledronic acid adalimumab, agalsidase beta, atezolizumab, azacitidine, basiliximab, bevacizumab, bevacizumab; among others.
As explained in Resolution 553-02 on the expansion and harmonization of coverage of medicines and high-cost procedures. As of September 2022, CNSS approved a budget of 1,000,000.00 RD$2,090,000.00 pesos as the coverage limit per member. These include a range of diseases that require high-cost treatment and are currently covered by the ARS.
The CNSS covers a total of 89 high-cost drugs used to treat adult and childhood cancer, neoadjuvant, adjuvant and palliative care.
Abiraterone, megestrol acetate, folinic acid; ibandronic acid, zoledronic acid, albumin + paclitaxel, anastrozole, aprepitant; azathioprine, basiliximab. Bendamustine, bevacizumab, bicalutamide, bleomycin, bortezomib; busulfan, capecitabine, carboplatin, cetuximab, cyclophosphamide; off market In addition to other higher-cost products.
Publishers Mindscape Developers P.F. Magic Release date 1998 Genre Simulation Game rating Description of the…
Editors Activision, Inc. Developers superego games Release date 2006 Gender Adventure Game Rating Game Description…
Editors Terraglyph Interactive Studios, Warner Bros. Interactive Entertainment. Developers Terraglifo interactive studios Release date nineteen…
Editors Sega, Digital Images, Screaming Villains, Limited Run Games Developers Digital Images, Inc. Release date…
Editors Davilex Games BV Developers Davilex Games BV Release date 1998 Gender Careers Game Rating…
Editors Sony Computer Entertainment, Disney Interactive Studios Developers High voltage software Release date 2002 Gender…